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Edited by Alex TokerOver the last decade, the CMGC kinase DYRK2 has been
reported as a tumor suppressor across various cancers trig-
gering major antitumor and proapoptotic signals in breast,
colon, liver, ovary, brain, and lung cancers, with lower DYRK2
expression correlated with poorer prognosis in patients. Con-
trary to this, various medicinal chemistry studies reported
robust antiproliferative properties of DYRK2 inhibitors,
whereas unbiased ‘omics’ and genome-wide association study-
based studies identified DYRK2 as a highly overexpressed ki-
nase in various patient tumor samples. A major paradigm shift
occurred in the last 4 years when DYRK2 was found to regulate
proteostasis in cancer via a two-pronged mechanism. DYRK2
phosphorylated and activated the 26S proteasome to enhance
degradation of misfolded/tumor-suppressor proteins while also
promoting the nuclear stability and transcriptional activity of
its substrate, heat-shock factor 1 triggering protein folding.
Together, DYRK2 regulates proteostasis and promotes protu-
morigenic survival for specific cancers. Indeed, potent and se-
lective small-molecule inhibitors of DYRK2 exhibit in vitro and
in vivo anti-tumor activity in triple-negative breast cancer and
myeloma models. However, with conflicting and contradictory
reports across different cancers, the overarching role of DYRK2
remains enigmatic. Specific cancer (sub)types coupled to
spatiotemporal interactions with substrates could decide the
procancer or anticancer role of DYRK2. The current review
aims to provide a balanced and critical appreciation of the
literature to date, highlighting top substrates such as p53,
c-Myc, c-Jun, heat-shock factor 1, proteasome, or NOTCH1, to
discuss DYRK2 inhibitors available to the scientific community
and to shed light on this duality of protumorigenic and anti-
tumorigenic roles of DYRK2.
Protein kinase DYRK2 is a member of the Dual-specificity
tYrosine phosphorylation–Regulated Kinase (DYRK) family,
which in turn belongs to the Cyclin-dependent kinases,
Mitogen-activated protein kinases, Glycogen synthase kinases,
and CDC-like kinases (CMGC) superfamily within the kinase
complement of the human genome (1). The DYRK family
consists of 5 members divided into two classes: Class I is
comprised of DYRK1A and DYRK1B, whereas class II is
comprised of DYRK2, DYRK3, and DYRK4 (Fig. 1A). DYRK2
is a class II DYRK that exhibits various structural features such* For correspondence: Sourav Banerjee, s.y.banerjee@dundee.ac.uk.
© 2021 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for
BY license (http://creativecommons.org/licenses/by/4.0/).as the NAPA or N-terminal autophosphorylation accessory
domains (yellow/orange), DYRK-homology domain (green),
activation loop segment (purple), nuclear localization
sequence (red), the CMGC family–specific insert domain
(gray) (Fig. 1B) most of which are conserved across the DYRK
family (2). In DYRK2, specific loss-of-function mutations have
been reported in cancer (Fig. 1B), which affect either the ac-
tivity of the kinase or impede its ability to form functional
complexes with interactors (3). In fact, phosphoproteomics
studies show that these cancer mutations significantly alter
substrate specificity of DYRK2 in cells (3). Class I DYRKs
exhibit two distinct nuclear localization sequences and a
stretch of polyserine and polyproline (PEST, Pro-Glu-Ser-Thr)
domain with no distinct NAPA domains as in class II
paralogues (Fig. 1C). Despite subtle structural differences be-
tween class I and II members, all DYRK isoforms exhibit a
highly conserved autophosphorylation-mediated activation
mechanism (4). During translation, hydroxylation of a highly
conserved proline residue (proline441 for hDYRK2) on the
inert/nascent kinase domain of DYRKs triggers a tyrosine
autophosphorylation event within the activation loop (tyro-
sine382 for hDYRK2), which leads to conversion of the inac-
tive to the active conformation of the kinase (5). In the fully
active form, the DYRK transition from a tyrosine-
phosphorylating kinase to a serine-/threonine-directed ki-
nase, thus acquiring the label ‘dual specificity’ (2, 4). The
NAPA and DYRK-homology domain domains are thought to
promote the structural integrity of the nascent kinase enough
to execute the indispensable autophosphorylation event (2).
The CMGC-specific insert is conserved across the CMGC
kinase superfamily and is proposed to play important roles in
stabilization of the tertiary structure of the kinase and pro-
moting complex formation with interactors/substrates (6).
Like most CMGC kinases, DYRKs have an amino acid motif
of preference on their substrates. DYRKs prefer an arginine (R)
at the −3 position of the phosphoserine/threonine residue
along with a strong preference for a proline (P) at +1: Rxx(pS/
T)P motif (7). Being a preferred motif across all members,
redundancies have been observed wherein multiple CMGC
kinases phosphorylate the same site on the substrate (reviewed
in Boni et al. [8]). Although both the −3 R and +1 P are
strongly preferred, some DYRK substrates lack the +1 P such
as histone H3 for DYRK1A (9), 26S proteasome regulatory
subunit 6B RPT3 (10), and heat-shock factor 1 (HSF1) (11) for
DYRK2, whereas the −3 R is lacking on multiple DYRK2
substrates such as p53 (12, 13), c-Jun, c-Myc (14), and SIAH2J. Biol. Chem. (2021) 296 100233 1
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Figure 1. DYRK2 belongs to the DYRK family within the CMGC superfamily and is mutated in cancer. A, DYRK2 is a class II DYRK on the CMGC
superfamily branch of the kinome. B, structure of DYRK2 indicating the major structural domains and cancer-associated mutations (derived from PDB ID:
3K2L) with a hypothetical effect on DYRK2 structure/function. C, the domain diagram providing a 2D comparative image of the domains of class II DYRK2
and class I DYRK1B. Class I DYRKs exhibit two NLS sequences, a C-terminal PEST domain and a lack of NAPA domain characteristic of class II. The auto-
phosphorylation of Tyr and hydroxylated Pro Y382/P441 (DYRK2) and Y273/P332 (DYRK1B) are shown. CMGC, Cyclin-dependent kinases, Mitogen-activated
protein kinases, Glycogen synthase kinases, and CDC-like kinases; DYRK, Dual-specificity tYrosine phosphorylation–Regulated Kinase; NAPA, N-terminal
autophosphorylation accessory; NLS, nuclear localization sequence; PEST, Pro-Glu-Ser-Thr.
JBC REVIEW: DYRK2 in cancer(15). For those lacking the +1 P, the substrates have exhibited
no redundant kinases within the related CMGC superfamily
thus far (10). Among the DYRKs, DYRK2 often functions in
tandem with related CMGC kinase, GSK3, in sequentially
phosphorylating various substrates (7, 9, 16, 17). DYRK2
provides a priming phosphorylation for further GSK3 activity
(7, 9, 16, 17). DYRK2 has been identified in all eukaryotes (10,
18), and interestingly across all orthologues, the conserved
biological function of the DYRK2 isoform is regulation of cell
division and/or tissue development (10, 18). A recent work
has shown that DYRK2 is an essential kinase during embryo-
genesis, and mouse embryos with homozygous deletion of
DYRK2 exhibit stunted development and pups die just before
birth (19).
Of all the DYRK isoforms, DYRK2 is the only member that
functions as a kinase activity–independent scaffold for an E3
ubiquitin ligase complex (20–24). DYRK2 is an integral part of
the EDVP (EDD [ubiquitin protein ligase] + DDB1 [damage-
specific DNA-binding protein] + VPRBP [HIV-1 Vpr-binding
protein]) E3 ubiquitin ligase complex that carries out
phosphorylation-mediated degradation of various cell cycle
components to ensure smooth transition of G2/M stages of
cell cycle (20–24). Some of the cancer mutations in Figure 1B
are thought to affect efficient EDVP complex formation (3).
Thus, over the past few decades, many groups have identified
various molecular mechanism and substrates for DYRK2
playing diverse roles in cellular growth, proliferation, and2 J. Biol. Chem. (2021) 296 100233developmental processes with a focal point being its role in
cancer (10, 25–28).
Besides DYRK2, the other DYRK isoforms, especially the
class I’s, have a long history in the field of cancer. Although
DYRK1B has an overall protumorigenic role specifically in
pancreatic and ovarian cancers, DYRK1A exhibits a more
controversial role with reports of both protumorigenic and
antitumorigenic mechanism in different cancers (reviewed in
Boni et al. [8]). Within the class II DYRKs, very little is known
about DYRK3 and DYRK4 with limited literature pointing to a
more protumorigenic role for both (29, 30). DYRK2, on the
other hand, is the most extensively studied class II isoform,
and the high-profile substrates reported, such as p53 (12, 13),
c-Jun (14), c-Myc (14), NOTCH1 (31), HSF1 (11), 26S pro-
teasome (10, 25, 26), and SIAH2 (15, 31), have brought the
kinase to the forefront of oncology research. For the past
2 decades, multiple studies have reported an overarching tu-
mor suppressor role of DYRK2 across various cancers
(reviewed in Yoshida and Yoshida [27]), with antitumorigenic
roles including regulation of cell cycle, apoptosis, epithelial–
mesenchymal transition (EMT), cancer stemness, and anti-
metastatic roles (reviewed in Yoshida and Yoshida [27]). On
the other hand, since 2016, multiple studies report major
protumorigenic roles of DYRK2 (10, 11, 25, 26), and a few
studies have identified DYRK2 as a possible cancer driver
(32–34). Furthermore, mRNA expression analyses from The
Cancer Genome Atlas (TCGA) tumors along with matched
Figure 2. DYRK2 regulates proteostasis via a two-pronged mechanism.
DYRK2 phosphorylates and upregulates the activity of the 26S proteasome,
which reduces proteotoxic stress by degrading misfolded/unfolded pro-
teins. In parallel, DYRK2 triggers phosphorylation-mediated activation of
HSF1, which promotes transcriptional upregulation of chaperones that
promotes folding of misfolded/unfolded proteins. Proteasome inhibitors
(PIs) such as bortezomib, carfilzomib, and ixazomib inhibit the proteasome
and result in enhanced proteotoxic stress because of toxic protein aggre-
gates. Proteasome inhibition by PIs triggers indirect activation of the HSF1
pathway to compensate for the loss of proteasome activity thereby
decoupling the proteasome dependence of cancer. HSF1, heat-shock
factor 1.
JBC REVIEW: DYRK2 in cancernormal controls reveal that the majority of cancers have higher
median expression of DYRK2 than adjacent normal tissues
(26), and a similar pattern has been shown for DYRK2 protein
levels in some tumor types (11, 26). All of these data suggest
that DYRK2 might be an excellent potential drug target. With
such high profile, oncology-related substrates, could the
function of DYRK2 differ based on cancer type or cell type? To
shed some light onto this question, this review will re-examine
the current literature on the role of DYRK2 in cancer and
follow up with existing knowledge of small-molecule inhibitors
developed to target DYRK2.
DYRK2 regulates proteostasis: an oncogenic role
DYRK2 maintains proteostasis of cancer cells by regulating
two major players of the proteotoxic response pathway, which
promotes the proper folding and/or degradation of proteins
(Fig. 2). More than 90% of all solid human tumors carry
numerous aberrations in chromosomes, referred to as aneu-
ploidy (35). As a result of their severe aneuploidy, cancer cells
are exposed to proteotoxic stress that increases the amount of
toxic, unfolded proteins in the cell (36, 37). To survive pro-
teotoxic stress, cancer cells can either increase protein folding
capacity (controlled by the transcription factor HSF1) or in-
crease the degradation of the misfolded/aggregated proteins
(via the 26S proteasome and/or autophagy). DYRK2 phos-
phorylates and activates both HSF1 and the 26S proteasome
and thereby activates the proteotoxic stress pathway promot-
ing tumorigenesis in cancers such as triple-negative breast
cancer (TNBC) and multiple myeloma (MM).
DYRK2 regulates 26S proteasome function
In 2016, an RNAi kinase screen identified DYRK2 as a
kinase-regulating 26S proteasome activity (10). The study
showed that DYRK2 depletion either by si/shRNA or CRISPR/
Cas9 KO led to a 30 to 40% decrease in proteasome activity
(10). The mature 26S proteasome is a complex of more than 30
distinct subunits that catalyzes 80% of eukaryotic protein
degradation and harbors three distinct peptidase activities in
the core subunit (chymotryptic, tryptic, and caspase-like)
(38, 39). Besides the core of the proteasome, the complex
also consists of the 19S regulatory subunit that binds to
ubiquitylated proteins, whereas a six-membered ATPase ring
hydrolyzes the protein into a polypeptide chain for entry into
the peptidase core for degradation (40). Interestingly, DYRK2
phosphorylates the Rpt3 subunit on the ATPase ring of the
19S subunit of the proteasome on an evolutionarily conserved
Thr25 site (10). Rpt3 pT25 had been previously reported by
Steve Gygi’s group in their 2008 work on quantitative phos-
phoproteomics of mitosis (41), but the function of the phos-
phorylation was not known. A phospho-specific antibody
generated against pT25 Rpt3 showed that the site is dynami-
cally upregulated during G2/M stage of the cell cycle and that
serum starvation leads to loss of Thr25 phosphorylation (10).
Furthermore, CRISPR/Cas9 knock-in of a phospho-deficient
Thr25Ala on Rpt3 mimics the DYRK2 KO phenotypes in
cells wherein there is a delay in mitotic progression, slower cellproliferation rates, and inhibition of all three peptidase activ-
ities of the 26S proteasome (10). The 26S proteasome degrades
nearly 80% of all eukaryotic proteins, and hence, a 30% loss in
activity leads to significant proteotoxic stress and consequent
cell death in breast cancer cells (10). Intriguingly, DYRK2 KO
cells were significantly more sensitive to the proteasome in-
hibitor, bortezomib, suggesting DYRK2 could be a possible
therapeutic target for treatment of cancer (10). Indeed, in an
ectopic nude mouse xenograft model, DYRK2 KO and T25A
Rpt3 knock-in cells were less efficient in generating a tumor as
compared to parental cells (10). This study further established
the DYRK2-proteasome axis as potentially tumor promoting
because higher expression of DYRK2 significantly correlated
with higher mortality and poorer relapse-free survival in pa-
tients with breast cancer (10). In fact, inhibition or genetic
depletion of DYRK2 tipped the scales of proteostasis in TNBC
and MM cells. DYRK2 mRNA levels are higher in newly
diagnosed and relapsed MM than normal donors (26). In fact,
mice bearing syngrafted/xenografted myeloma cells with ge-
netic depletion of DYRK2 exhibit significantly slower myeloma
disease progression and reduced bone degeneration (26).
Furthermore, bortezomib-resistant RPMI8226 myeloma cells
express higher protein levels of DYRK2 than nonresistant
RPMI8226 (26), suggesting that DYRK2 might play a role inJ. Biol. Chem. (2021) 296 100233 3
JBC REVIEW: DYRK2 in cancerdriving drug resistance in some myeloma cases. The potent
and selective DYRK2 inhibitor, LDN192960, induces cytotox-
icity in myeloma cells both in vitro and in vivo with minimal
off-target effects (26). The fact that the DYRK2 inhibitor al-
leviates myeloma burden in vivo suggests DYRK2 could indeed
be a viable in vivo target for myeloma therapeutics. Resistance
to proteasome inhibitors have been reported in patients, and
this is either brought about by cancer mutations in the pro-
teasome core or via upregulation of HSF1-mediated proteo-
toxic response pathway.
DYRK2 phosphorylates HSF1 and modulates proteotoxic
response
The transcription factor HSF1 is the master regulator of
proteotoxic stress responses and supports oncogenesis by
helping cancer cells cope with the proteotoxic stress associated
with both aneuploidy and oncogenic mutations. This has been
demonstrated by the reduced susceptibility of Hsf1-KO mice
to tumor formation driven either by Ras/p53 mutations or by
chemical carcinogens (42, 43). Furthermore, high levels of
HSF1 expression associate with poor outcome of various
cancers (44). Upon proteotoxic stress, HSF1 is activated,
translocates to the nucleus (45), and initiates the transcription
of heat-shock proteins. Heat-shock proteins then function as
molecular chaperones, protecting cells against proteotoxic
stress by assisting in protein folding (46). HSF1 activity and
stability are tightly controlled by multiple post-translational
modifications (47). Among these, phosphorylation of serine
320 and serine 326 is associated with stability and nuclear
accumulation followed by enhanced transcriptional activity of
HSF1 (48–50). DYRK2 positively regulates HSF1 nuclear sta-
bility and activity, by phosphorylating it at Ser320 and Ser326
in TNBC cells (11). Indeed, DYRK2-depleted TNBC cells were
far more sensitive to heat shock–mediated proteotoxic stress
than parental cells, thus corroborating that DYRK2 plays a
major role in maintaining proteostasis in TNBC cells. This link
between DYRK2 and HSF1 is also observed in TNBC tumor
samples, wherein a marked correlation was observed between
high DYRK2 levels and high nuclear HSF1 levels.
The HSF1 pathway and the proteasome are not just two of
the main pathways maintaining cell proteostasis, but they are
interconnected and can compensate for each other. As
mentioned before, proteasome inhibitors lead to the activation
of HSF1 (Fig. 2) in an effort to protect the cell against the
accumulation of toxic proteins (51, 52). The cytoprotective
response mediated by HSF1 counteracts the cytotoxic effect of
proteasome inhibitors (51–53), and thus, HSF1 inhibition
might be effective to overcome proteasome inhibitor resistance
in cancer cells. In that sense, a DYRK2 inhibitor induced
cytotoxicity even in MM cells resistant to proteasome in-
hibitors (25, 26), suggesting that in fact DYRK2 inhibition
might be targeting different complementary pathways. This
observation was further echoed by a recent study showing that
MM cells were extremely sensitive to increased temperatures
and heat shock (54). In fact, combining heat shock with pro-
teasome inhibitors led to higher accumulation of misfolded4 J. Biol. Chem. (2021) 296 100233proteins leading to acute proteotoxic stress and apoptosis in
the myeloma cells (54). Because cancer cells harbor signifi-
cantly higher misfolded proteins than normal cells, targeting
DYRK2 could indeed tip the scales for proteostasis in malig-
nant cells and provide a significant therapeutic window for
targeting specific cancers. This is indeed the case because
normal/noncancerous cells were far more resistant to DYRK2
inhibitors (25, 26). Thus, targeting DYRK2 can significantly
affect proteostasis (Fig. 2) via perturbation of both HSF1 and
26S proteasome activity leading to cancer cell death.
Hence, in the context of TNBC and MM, DYRK2 plays an
overarching role as an oncogenic kinase and a potential ther-
apeutic target.
DYRK2-p53 tumor suppressor link
A major molecular mechanism by which DYRK2 has been
reported to exhibit the antitumorigenic role is via phosphor-
ylation of tumor suppressor p53 on serine46 (Ser46). Upon
genotoxic stress, energy stress, or heat shock, multiple CMGC
kinases such as homeodomain-interacting protein kinase
(HIPK2), mitogen-activated protein kinase p38α, and DYRK2
can phosphorylate p53 on Ser46, which triggers transcription
of proapoptotic genes leading to cell death or cell senescence
(reviewed in Liebl and Hofmann [55]). Upon DNA damage,
DYRK2 is phosphorylated by ataxia-telangiectasia mutated
kinase, which protects DYRK2 from proteasomal degradation
leading to its nuclear accumulation where it phosphorylates
p53 on Ser46 and promotes its transcriptional tumor sup-
pressor activity (12, 13). Although phosphorylated Ser46 on
p53 is indeed a marker for its tumor suppressor role, DYRK2
by no means is the exclusive kinase here. With multiple ki-
nases including PKCδ, HIPK2, ataxia-telangiectasia mutated
kinase, and p38α phosphorylating Ser46 upon genotoxic stress
(55), it is hard to decipher to what extent DYRK2 contributes
to this tumor suppressor role. Furthermore, p53 is mutated or
truncated in a vast number of solid tumors and cancer patients
with altered p53 exhibit significantly poorer survival (56, 57).
Mutated p53 often exhibits stoichiometrically lower phos-
phoSer46 (58) and has been reported to trigger pro-oncogenic
functions upon phosphorylation (59). This suggests that p53
phosphorylated on Ser46 serves as a tumor suppressor only in
the few percentage of cancers containing WT p53 where pa-
tients exhibit better chances of survival.
Multiple publications carrying out sequencing or immu-
nohistochemistry to study mRNA/protein levels of DYRK2
have suggested that DYRK2 is a tumor suppressor in colo-
rectal (60–63), liver (64), brain (65), and lung cancers (66, 67)
and that the kinase promotes chemosensitivity in ovarian
cancer (68). However, ovarian, liver, brain, lung, and colorectal
cancers exhibit some of the highest mutations and variant allele
frequencies in p53 compared with other cancer types (56, 57,
69). Thus, it is unclear to what extent DYRK2’s phosphorylation
of p53 could play as a tumor-suppressive role in these solid
tumors exhibiting p53 mutation or loss. Furthermore, in
endothelial cells, the pan-DYRK inhibitor, harmine (albeit with
possible off-target effects), promotes p53 phosphorylation on
Figure 3. Overall summary of DYRK2 in neoplasia. The figure provides a holistic view of the various reported roles of DYRK2 in different forms of cancers.
For each cancer, the various interactors/substrates/effectors of DYRK2 are highlighted either in green (tumor-suppressor role) or in red (protumorigenic role).
The cancer models/tools (cell-based, mouse models, patient samples, DYRK2 inhibitor) used to derive the respective conclusions are also shown. Direct
DYRK2 substrates are shown with the added (P) phosphate, and conclusions based on sequencing or immunohistochemistry are also highlighted. Gray
arrows indicate those cancers where controversial or conflicting reports have been documented.
JBC REVIEW: DYRK2 in cancerSer15, Ser20, and Ser37 (70), leading to higher p53 protein
levels upon DNA damage (70, 71). Seemingly, in this case,
DYRK2 inhibition led to tumor suppression. Hence, it is also
important to decipher the molecular functions of DYRK2 in
noncancer models or as a potential cancer driver. A recent
unbiased deep multiomics study looking at the proteome,
phosphoproteome, and transcriptome of murine high-grade
brain cancer glioma model reported 41 kinases including
DYRK2 exhibiting higher activity and rewired substrate
signaling (34). Furthermore, the glioma murine model was
generated by intracranial implantation of genetically engi-
neered p53 null astrocytes, thus making the tumor-
suppressor role of DYRK2-p53 axis highly untenable in this
model.
Besides solid tumors, chronic myeloid leukemia (CML) cell
lines exhibit significantly lower protein levels of DYRK2 than
other hematological cancer cell lines (72). Interestingly, tran-
scriptional upregulation of DYRK2 inhibits survival and self-
renewal of CML stem/progenitor cells via c-Myc depletion
and p53 activation (72). This tumor-suppressor role of DYRK2
seems to be CML specific because all other leukemia subtypestested exhibited naturally elevated protein levels of DYRK2 at
basal conditions (72), suggesting alternate driving mechanisms
for tumorigenesis. Hematological malignancies exhibit fewer
p53 mutations/loss (56, 57), and hence, DYRK2 could indeed
be a tumor suppressor in specific subtypes such as CML. On a
similar note, silencing DYRK2 has been reported to increase
cell proliferation and reverse cell adhesion–mediated drug
resistance in non-Hodgkin’s lymphoma cell lines (73).
Intriguingly, MM cells are highly sensitive to DYRK2 inhibi-
tion irrespective of p53 status (25, 26). Because DYRK2 inhi-
bition in myeloma tips the balance of proteotoxic stress
(26, 54), all cells whether p53 WT (such as cell line MM.1S) or
mutated (such as cell lines RPMI8226 and U266B1) die (26).
This suggests that in myeloma, the role of DYRK2 as an
oncogenic driver probably plays a far greater role than its
tumor-suppressor function potentiated by p53 phosphoryla-
tion. Hence, stratification of cancer subtypes before assigning
molecular functions to DYRK2 is important. However, DYRK2
has tumor-suppressor mechanisms beyond p53 involvement,
and it is important to investigate the diverse mechanisms at
play to derive a larger perspective (Fig. 3).J. Biol. Chem. (2021) 296 100233 5
Table 1
DYRK2 molecular mechanism and substrates/partners listed along with reported phosphorylation sites, overarching role, and the unan-
swered questions raised by each study
Cancer Molecular partner Phosphosite Reported role Pending question/issue
Breast 26S proteasome/
RPT3 (10, 25, 26)
Thr25 Oncogenic; regulates proteostasis Data specific for triple-negative breast cancer
subtype.
HSF1 (11) Ser320, Ser326 Data specific for triple-negative breast cancer
subtype; possible redundancy with other
kinases.
SNAIL (83) Ser104 Tumor suppressor; EMT downregulation Data heavily reliant on ectopic overexpression;
possible redundancies with other kinases
NOTCH1 (31) Thr2512 Tumor suppressor; reduces invasion Redundancies with other kinases; C-Myc
pSer62 can be oncogenic; redundancies
with other kinases; small sample sizes used
for in vivo work.
C-Myc (14) Ser62
C-Jun (14) Ser243 Possible redundancies with other DYRK fam-
ily kinases
p53 (12, 13) Ser46 Tumor suppressor; proapoptotic upon geno-
toxic stress
Most tumors are p53 mutated/null and
mutated p53 becomes oncogenic; DYRK2
mRNA strongly overexpressed in breast
cancer overall.
CDK14 (129) n/a Tumor suppressor; reduces invasion and
proliferation
No specific mechanism reported on how
DYRK2 regulates CDK14 transcription.
Lung SIAH2 (86) Ser16, Thr26,
Ser28, Ser68,
Thr119
Tumor suppressor; modulates hypoxia
response pathways
DYRK2 is strongly overexpressed in lung




n/a Oncogenic; degrades proapoptotic MOAP1;
chemoresistance
Phosphorylated substrate (if any) not
established.
SNAIL (68) Ser104 Tumor-suppressor; EMT downregulation;
chemoresistance
Data heavily reliant on ectopic overexpression;
possible redundancies with other CMGC
kinases; 2 cell lines used only.
Brain PI3K/AKT/GSK3β (65) n/a Tumor-suppressor; EMT downregulation DYRK2 mRNA is strongly overexpressed in
glioma; DYRK inhibitors kill glioma cells.
Unknown (unbiased
multiomics) (34)
Oncogenic; DYRK2 increased activity and
rewired signaling
Multiomics data derived from p53 null murine






Thr25 Oncogenic; regulates proteostasis n/a
Leukemia p53/c-myc/KLF4 (72) n/a Tumor suppressor; reduces cancer stemness Data specific for chronic myeloid leukemia
subtype.
Liver p53/c-myc (62, 64, 130) n/a Tumor suppressor; EMT downregulation; re-
duces invasion; chemoresistance
p53 and c-Myc have extensive oncogenic
mutations reported in liver cancer.
LNC-HC/hsa-miR-
183-5p (104)
Tumor suppressor; transcriptional upregula-
tion of DYRK2
Multiple tumor suppressors upregulated
including DYRK2; no specific DYRK2
mechanism reported.
Colorectal p53 (12) Ser46 Tumor suppressor; proapoptotic upon geno-
toxic stress
Most colorectal tumors are p53 mutated/null,
and mutated p53 becomes oncogenic;
DYRK inhibitor promotes p53
phosphorylation.
DNMT1 (103) n/a Tumor suppressor; epigenetic downregulation
of DYRK2
No specific DYRK2 mechanism reported.
miR-622 (63) Tumor suppressor; EMT downregulation; re-
duces invasion
Lymphoma CDK2/p27Kip1 (73) n/a Tumor suppressor; EMT downregulation;
chemoresistance
Data specific for non-Hodgkin’s lymphoma
subtype.
CMGC, Cyclin-dependent kinases, Mitogen-activated protein kinases, Glycogen synthase kinases, and CDC-like kinases; DYRK, Dual-specificity tYrosine phosphorylation–
Regulated Kinase; EMT, epithelial–mesenchymal transition; HSF1, heat-shock factor 1; MOAP, modulator of apoptosis protein 1; NOTCH1, neurogenic locus notch homolog
protein 1; n/a, not directly reported.
Also, refer Figure 3.
JBC REVIEW: DYRK2 in cancerOther molecular mechanisms linking DYRK2 and cancer
Various p53-independent tumor-suppressor mechanisms
have been reported for DYRK2, while other substrates point to
an oncogenic role. Each mechanism focuses on specific cancer
types and subtypes (Fig. 3 and Table 1). The main substrates
and mechanisms are critically presented below.
c-Myc
DYRK2 has been reported to exhibit a p53-independent
tumor-suppressor role by phosphorylating c-Myc on
serine62 (Ser62) (14). c-Myc is a major proto-oncogenic
transcription factor known to be overexpressed and mutated
in various cancers (74). Post-translational modifications of
c-Myc have been a topic of much debate over the past 30 years6 J. Biol. Chem. (2021) 296 100233in which sequential phosphorylation of Ser62 and Threo-
nine58 (Thr58) seems to play major roles in c-Myc trans-
activation (75, 76). The consensus in the field is that Thr58 is a
GSK3-phosphorylation site while Ser62 seems to be the
priming site for GSK3 activity, and similar to phosphorylation
of p53 at Ser46, various CMGC kinases have been proposed
(75), including DYRK2 to phosphorylate c-Myc. Dual phos-
phorylation of c-Myc on Thr58 and Ser62 triggers binding to
an E3 ubiquitin ligase SCF-Fbxw7 (Skp-Cullen-F-box) and
consequent proteasomal degradation of c-Myc (14), thus
leading to the proposed tumor suppressor role of DYRK2. As
stated previously, transcriptional upregulation of DYRK2 in
CML promotes c-Myc degradation (72). In Burkitt lymphoma,
nearly 60% of patients exhibit mutation of the GSK3 site,
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phosphorylation (76), thus suggesting a tumor-suppressor role
of GSK3 in this context. However, increased Ser62 phos-
phorylation has been observed in immortalized cells compared
with primary cells (76), and monophosphorylation of Ser62 has
been linked to c-Myc stabilization and higher transcriptional
activity in multiple studies (78, 79). This indicates a similar
conundrum as observed with the p53 Ser46 site wherein
multiple kinases and diverse cancer subtypes exhibit altered
mechanisms of action of major cancer-associated genes such
as p53 and c-Myc.
c-Jun
A similar story is observed in case of c-Jun wherein two
phosphorylation sites serine249 (Ser249: a bona fide GSK3
site) and Ser243 (reported to be phosphorylated by DYRK2)
have been reported (14, 80). c-Jun is a transcription factor with
established oncogenic roles (80). Similar to c-Myc, the E3
ubiquitin ligase SCF-Fbxw7 degrades c-Jun upon dual phos-
phorylation of Ser249 and Ser243 (81). Unlike c-Myc, Ser243
on c-Jun could be a DYRK-specific site because a previous
study has elegantly ruled out most of the other CMGC kinase
families (80). The same study did, however, observe re-
dundancies between DYRK1A and DYRK2 for Ser243 on c-Jun
in vitro (80), which is not surprising because the site is a +1P.
In fact, dephosphorylation of Ser243 enhances c-Jun tran-
scriptional activity in patients with cervical cancer exhibiting
lower phosphoSer243 c-Jun in their tumors (82). Although the
question of intra-DYRK redundancy remains, phosphoSer243
on c-Jun could indeed be a tumor-suppressor marker in spe-
cific cancers.
SNAIL
DYRK2 has also been reported to phosphorylate the zinc
finger domain containing protein SNAIL that plays essential
roles during development by triggering EMT (68, 83). DYRK2
knockdown led to upregulation of mesenchymal markers with
consequent downregulation of epithelial E-cadherin mRNA in
colon cancer (61) and promotion of proliferation and migra-
tion of glioma cells (65). This observation was consistent with
other studies reporting downregulation of DYRK2 in meta-
static colorectal secondary tumors found in the liver (62).
SNAIL has been reported to be overexpressed in specific
cancers and promote oncogenic progression by promoting
EMT, invasion, and metastasis (83). DYRK2 phosphorylates
serine104 on SNAIL that provides a priming site for GSK3,
triggering the phosphorylation-mediated degradation of
SNAIL (68, 83). This mechanism of antitumorigenic activity by
DYRK2 is thought to promote chemosensitivity for ovarian
cancer cells (68). A follow-up study reports that the DYRK2-
mediated degradation of SNAIL is in fact reversed by p38α
kinase (84). Although an interesting molecular mechanism, in
both studies, DYRK2 ectopic overexpression has been carried
out to justify the phosphorylation. Overexpression of CMGC
kinases often leads to nonphysiological false-positive subcel-
lular localizations and substrate identifications because ofredundancy and high affinity for +1 P sites and hence further
tools need to be used to confirm the DYRK2–SNAIL
mechanism.
SIAH2
Seven In Absentia Homolog 2 or SIAH2 is an E3 ubiquitin
ligase that plays a major role in targeted degradation of various
proteins playing essential roles in regulating hypoxia (85).
SIAH2 specifically regulates hypoxic tumor microenvironment
by downregulation of key kinases in the Hippo signaling
pathway (85). Furthermore, higher expression of SIAH2 is
observed in lung cancer (86) and it plays oncogenic roles in
castration-resistant prostate cancer (87). Interestingly, DYRK2
phosphorylates SIAH2 on 5 residues Ser16, Thr26, Ser28,
Ser68, and Thr119. These modifications alter its subcellular
localization thereby rewiring SIAH2 substrate specificity (15).
SIAH2, in turn, is capable of degrading DYRK2 in specific
cancers thereby triggering a protumorigenic hypoxic micro-
environment (15, 85, 86). Some kinase redundancy has been
observed wherein p38α kinase is capable of phosphorylating
SIAH2 on same sites as DYRK2 (88); however, the DYRK2–
SIAH2 link points to an interesting interplay between a kinase
and a ubiquitin ligase regulating each other and thereby
balancing protumorigenic and antitumorigenic roles.
EDVP E3 ubiquitin ligase
As stated previously, DYRK2 forms a kinase-independent
scaffold for the EDVP E3 ligase complex and a recent study
has reported loss-of-function point mutations of DYRK2 in
cancer, which largely alters the interactome and substrate
specificity of DYRK2 (3). The recurrent mutations (Fig. 1B) are
thought to alter activity and/or formation of the EDVP com-
plex (3). As part of the EDVP complex, DYRK2 phosphorylates
and triggers degradation of multiple substrates such as
katanin p60 (KATNA1) (23), telomerase reverse transcriptase
(TERT) (22), and centrosome protein 110 (CP110) (21).
Phosphorylation-mediated degradation of these substrates are
required for proper cell cycle transitions especially the G2/M
stage. Cancer mutations could result in incomplete EDVP
complex formation, and incomplete EDVP can exhibit onco-
genic prosurvival role because DYRK2+EDD alone degrades
the proapoptotic factor modulator of apoptosis protein 1
independently of DDB1 and VPRBP in ovarian cancer (89).
The substrates of DYRK2–EDVP exhibit both protumorigenic
and antitumorigenic roles in various cancers thus adding
further complexity. Ovarian cancer patients with higher levels
of KATNA1 exhibit better overall survival (90); higher CP110
can decrease breast cancer cell invasion (91), yet lung cancer
tissue expresses higher CP110 than the normal lung (92), while
TERT is largely oncogenic (93). Thus, DYRK2–EDVP func-
tions are tumor specific.
STAT3
DYRK2 has been reported to phosphorylate signal trans-
ducer and activator of transcription 3 (STAT3) in vitro (94).
STAT3 is a transcription factor with both oncogenic andJ. Biol. Chem. (2021) 296 100233 7
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environments (reviewed in Galoczova et al. [95]). STAT3 is
phosphorylated on various residues upon interleukin/cytokine
stimulation, and the phosphorylation on serine727 (Ser727) is
thought to be an oncogenic biomarker in some subtypes of
breast cancer (96). Although Ser727 is thought to promote the
transcriptional activity of STAT3 (95), various kinases (CMGC
family and beyond) have been reported to target Ser727 which
is a +1P site (94). Thus, it is very difficult to dissect the
importance of DYRK2 alone in driving phosphoSer727-
mediated STAT3 activity.
TBK1
TANK-binding kinase 1 (TBK1) is an important upstream
regulator of innate immune transcription pathways triggering
type I interferon (IFN) translation and signaling in response to
pathogens (97). DYRK2 phosphorylates TBK1 at serine527,
which leads to phosphorylation-mediated degradation of
TBK1 and downregulation of type I IFN signaling upon viral
infection (97). Besides infections, the elevated presence of type
I IFN correlates with a favorable prognosis in patients with
different cancers (98, 99). In fact, reduced IFN-related gene
expression leads to an immunosuppressive tumor microenvi-
ronment resulting in immunotherapy resistance in many solid
tumors (99). Thus, DYRK2-mediated downregulation of IFN
signaling could play a major oncogenic role in triggering
immunotherapy resistance in various cancers. However, the
study reporting DYRK2 as the upstream kinase of TBK1 relies
on ectopic overexpression of DYRK2 to demonstrate direct
phosphorylation of a canonical +1P motif (97). There could be
redundancies with other CMGC kinases at that site which
needs to be addressed more thoroughly.
NOTCH1
In response to chemotherapeutic agents, DYRK2 facilitates
phosphorylation-mediated degradation of neurogenic locus
notch homolog protein 1 (NOTCH1), which acts as an anti-
proliferative mechanism in breast cancer cells (31). NOTCH1
is a single transmembrane receptor and triggers intracellular
signaling via binding to specific ligands (31). DYRK2 phos-
phorylates NOTCH1 on threonine2512 (Thr2512), which is
a +1P site. However, NOTCH1 exhibits both tumor suppres-
sor and oncogenic roles on a cancer-type basis (100). Inter-
estingly, Thr2512 lies in the intracellular carboxy-terminal
region of NOTCH1 that exhibits a PEST domain. The PEST
region is the target of multiple CMGC kinases such as
DYRK1A, HIPK2, CDKs, and GSK3, which triggers hyper-
phosphorylation and proteasomal degradation of NOTCH1
(reviewed in Lee et al. [101]). Thus, the redundancy conun-
drum remains to be solved to understand the function of
NOTCH1’s phosphorylation by DYRK2.
Transcriptional/epigenetic mechanisms
Besides modulating substrate phosphorylations, transcrip-
tional and epigenetic mechanisms of DYRK2 regulation have
also been proposed for some cancers. Specifically, the8 J. Biol. Chem. (2021) 296 100233downregulation of DYRK2’s gene expression has been linked
to increased stemness in breast cancer (102) and CML (72) via
upregulation of transcription factor Krüppel-like factor 4.
DYRK2 expression was also downregulated transcriptionally
by DNA methyltransferase 1 in colon cancer (103). The
DYRK2 promoter region exhibited a higher level of methyl-
ation in cancer tissues than healthy tissues while treatment of
cells with hypomethylating drug 5-azacytidine increased
DYRK2 mRNA and protein levels (103). Furthermore, DYRK2
was reported to downregulate oncogenic miR-622 expression
and reverse invasion of cancer cells (63), whereas long non-
coding RNA long noncoding RNA derived from hepatocytes
inhibits the proliferation of liver cancer cells by rescuing the
expression of DYRK2 (104).
To reiterate, multiple molecular mechanisms have been
proposed for DYRK2, and each mechanism is cancer-type or
subtype specific (Fig. 3 and Table 1). The controversial role of
DYRK2 is best highlighted in breast and lung cancers.
DYRK2 and breast cancer: a major controversy
TNBC
Various studies have focused on the role of DYRK2 in
TNBC (10, 11, 25, 26). These studies revealed that both
mRNA and protein levels of DYRK2 were higher in TNBC
tumors than adjacent normal breast tissues (26). Com-
plementing this information, a recent study with 715 samples
of patients with breast cancer have shown that high protein
levels of nuclear DYRK2 were associated with significantly
reduced cancer survival and a shorter time to recurrence
specifically within the TNBC subtype cohort (11). To test the
potential therapeutic value of targeting DYRK2 in TNBC,
three studies have compared the ability of parental and
DYRK2-deficient TNBC cell lines to produce tumors in vivo
(10, 25, 26). Crispr/Cas9-mediated DYRK2 deletion in MDA-
MB-231 or MDA-MB-468 cells showed that tumors derived
from TNBC–DYRK2–deficient cells had significantly slower
growth rates and lower tumor burden than those derived
from their parental cells. Importantly, two studies have
shown that treatment with the DYRK2 inhibitors, curcumin
and LDN192960, impaired growth of established TNBC tu-
mors (25, 26). In contrast with these findings, other studies
have used MDA-MB-231–derived xenografts and reported
DYRK2 control EMT by degrading SNAIL (83) and pro-
moting transcription factor Krüppel-like factor 4 expression
(102), thereby functioning as a tumor suppressor. Both the
studies used a DYRK2 overexpression system to show that
higher DYRK2 decreased tumor formation. One study re-
ported that mice xenografted with DYRK2-overexpressing
MDA-MB-231 cells showed few metastatic lesions and a
prolonged survival compared with those injected with con-
trol cells (83). In a second study, the authors compared the
number of tumors produced by injecting increasing numbers
of MDA-MB-231 cells with or without overexpressed DYRK2
(102). The authors used a sample size of n = 6 mice per
condition and show that the total number of tumors derived
from DYRK2-overexpressing cells was marginally lower than
JBC REVIEW: DYRK2 in cancercontrols (102). This is in sharp contrast to others reporting
DYRK2 depletion reduces proliferation and tumor formation
potential of MDA-MB-231 cells (10, 11, 25, 26, 105). Some of
these discrepancies might be due to the differential ap-
proaches used (DYRK2 knockdown/KO versus over-
expression systems) or due to underpowered sample sizes.
Furthermore, a phosphotyrosine proteomics study in TNBC
cells reported that DYRK2 was among the top 5 phosphor-
ylated proteins observed in aggressive basal-like TNBC cells
(105). Because there is no evidence of the activation loop
tyrosine exhibiting altered stoichiometric phosphorylation,
the high levels of phosphorylation observed could be due to
higher DYRK2 protein levels. In fact, siRNA knockdown of
DYRK2 in basal-like TNBC MDA-MB-231 and HCC1395
cells lead to reduced proliferation, invasion, and colony for-
mation potential of the cells (105).
Other breast cancer subtypes
Multiple studies looking at the role of DYRK2 in breast
cancer have used the hormone receptor–positive and HER2-
negative MCF7 cell line for xenograft studies. In the main
study that supports the tumor-suppressor role of DYRK2 in
breast cancer, the group identified DYRK2 as a priming kinase
for c-Jun and c-Myc (14). In this study, the authors used a
sample size of n = 3 mice per condition and carried out an
orthotopic mammary-fat-pad breast cancer xenograft
comparing MCF7 control cells and stable DYRK2 knockdown
cells to investigate their ability to produce tumors (14). They
found that DYRK2 knockdown cells clearly produce bigger
tumors. Furthermore, DYRK2 knockdown cells showed higher
invasion potential in vivo in an intracardiac injection model
(n = 6 mice per condition). The same shRNA DYRK2 depleted
cells were used in other studies as well to report the various
tumor-suppressor roles of DYRK2 (102, 106). From the study
with 715 samples of patients with breast cancer, no correlation
was observed between DYRK2 expression and poor outcome
in any of the receptor-positive breast cancer subtypes (11).
However, TCGA data suggest that mRNA expression of
DYRK2 is higher in breast invasive carcinoma and that higher
DYRK2 expression correlates with poor survival in overall
patients with breast cancer (8, 10, 26). Because mRNA and
protein levels sometimes do not correlate, larger analysis
looking at DYRK2 protein levels are needed to reach a finite
conclusion.
The best way forward is to generate a conditional lox-cre
mousemodel forDYRK2and generate hemizygous/homozygous
deletion of DYRK2 in different subtypes of breast cancer genet-
ically engineered mouse models (GEMMs) (107). Comparative
tumor growth in the DYRK2 null versus parental GEMM over
different subtypes would be a good way of addressing the
pending questions on role of DYRK2 in breast cancer.
DYRK2 in lung cancer: unresolved issues
In 2003, the chromosome 12 region 12q13-14 was found to
be amplified in adenocarcinomas of the lung and esophagus,
and one of the resident genes, DYRK2, was significantly
overexpressed in tumor samples as compared with normaltissues (33). In fact, DYRK2 exhibited the highest mRNA
overexpression and highest copy numbers in tumors compared
with normal tissue and other genes located in the 12q13-14
chromosomal region, suggesting that the overexpression of
DYRK2 is the driving force behind the amplicon (33). This is
reiterated in the TCGA lung adenocarcinoma and esophageal
cancer cohort wherein tumor samples expressed higher
DYRK2 mRNA than normal tissue (8). However, two inde-
pendent studies report that higher protein or mRNA expres-
sion of DYRK2 is a favorable marker in pulmonary
adenocarcinoma (66) and non–small-cell lung cancer
(NSCLC) (67). In fact, pulmonary adenocarcinoma patients
with higher DYRK2 expression exhibited a substantially higher
5-year survival than the group with lower DYRK2 expression.
The higher DYRK2 levels associating with negative lymphatic
invasion (66). Although the response rates to chemotherapy
between the DYRK2-positive and DYRK2-negative patients
were not different, patients with DYRK2+ tumors in recurrent
NSCLC were suggested to have better outcome with chemo-
therapy (67). Mechanistically, in lung adenocarcinoma and
squamous-cell lung cancer, E3 ubiquitin ligase SIAH2 targets
DYRK2 for proteasomal degradation (86). SIAH2 protein and
mRNA levels were found to be higher in samples of patients
with lung cancer and exhibited a negative correlation with
DYRK2 expression (86). Overall, the exact role of DYRK2 in
lung neoplasia is still up for debate. Hence, using a similar
strategy as suggested previously to generate conditional
DYRK2 depletion in genetically engineered lung cancer mouse
models for NSCLC, squamous-cell lung cancer, and other
subtypes (108) could provide more clarity to this debate.
As reported previously, various global unbiased studies in
various cancers have reported DYRK2 as a potential cancer
driver with increased copy numbers, overexpression, and
higher activity (32–34). On a similar note, a study using in-
tegrated high-resolution microarray analysis of gene copy
number and expression in head and neck squamous-cell car-
cinoma cells reported that DYRK2 had the highest copy
number and clear overexpression when compared with other
genes in the 12q chromosomal amplicon (109). Furthermore,
transcriptomics of blood identified DYRK2 as 1 of 10 potential
prognostic biomarkers elevated in high-grade precancerous
cervical lesions (110). Thus, unbiased identification of DYRK2
as a protein/kinase involved in potential protumorigenic role
along with its substrates such as p53, c-Myc, and c-Jun further
fuels the need to stratify cancers into subtypes before
embarking on DYRK2 molecular studies. This duality of pro-
tumorigenic and antitumorigenic roles has been reported for
the paralogue DYRK1A as well (111, 112) (Fig. 3 and Table 1),
and hence, there is a clear precedence for such controversial
roles in the DYRK family. One way of deconvoluting cancer-
type and cell-type functions of a controversial kinase is by
generating further tools such as potent and specific small-
molecule kinase inhibitors.
Small-molecule inhibitors of DYRK2
Over the past three decades, various studies have been
carried out to identify small-molecule inhibitors of kinasesJ. Biol. Chem. (2021) 296 100233 9
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highly successful therapeutic targets and treatment options
(113, 114). For the DYRKs, more than 60 reported small-
molecule inhibitors have been published or are available in
the public domain. ChEMBL (https://www.ebi.ac.uk/chembl)
predicts that there are >1500 potential small molecules that
can bind and possibly inhibit DYRK2, including established
anticancer drugs sunitinib, erlotinib, afatinib, ruxolitinib,
and crizotinib. A significant effort has been focused on
development of DYRK1A small-molecule inhibitors because
DYRK1A has established roles in neurodegenerative disorders.
Consequently, early on the only available DYRK2 inhibitors
were those targeting DYRK1A with off-target activity on
DYRK2. DYRKs are canonical CMGC kinases and broad-
spectrum ATP-competitive kinase inhibitors such as staur-
osporine and its derivatives inhibit DYRK2 at low nanomolar
concentrations (https://www.kinase-screen.mrc.ac.uk/kinase-
inhibitors). Although there is a high degree of conservation
between the kinase domains of class I and class II DYRKs,
structural studies indicated that subtle amino acid sub-
stitutions in the hydrophobic inhibitor–docking pocket be-
tween DYRK1A and DYRK2 could confer significant degrees
of inhibitor specificity (2). Interestingly, these amino acid
substitutions contributed to the development and identifica-
tion of various class-specific and often isoform-specific in-
hibitors for the DYRKs. Indeed, compound 5j that exhibited
more than 100-fold sensitivity for DYRK1A over DYRK1B has
no activity for class 2 DYRKs (115). Cocrystallization studies
revealed that specific isoleucine to valine replacements in the
docking site of curcumin resulted in a larger pocket in the class
I DYRKs and thus reduced the shape complementarity to the
inhibitor (25). Similarly, ID-8 an indole derivative exhibits an
IC50 of <100 nM for class 1 DYRKs but >10 μM for class 2
DYRKs, suggesting significant room for developing specific
inhibitors for the kinases (116). Similarly, β-carboline de-
rivatives such as harmine or AnnH75 exhibit more in vivo and
in vitro potency for class I than class II DYRKs (Table 2).
However, the benzimidazole derivatives such as INDY, TG003,
and DYR219 exhibit a pan-DYRK activity in vitro and in vivo
(Table 2) and have been reported to trigger degradation of
DYRK proteins when treated in cells (117, 118). This might
explain some of the pronounced in vivo efficacy compared
with in vitro observations for DYRK inhibitors wherein pro-
longed treatment leads to inhibition + degradation of the
DYRK target, leading to a significant phenotype. Some pro-
miscuous casein kinase inhibitors derived from benzimidazole
potently inhibited DYRK1A and DYRK2 in vitro (119, 120).
Silmitasertib (CX-4945), a potent and selective inhibitor of
CK2 (with IC50 of 1 nM in vitro), is an orally bioavailable drug
currently in phase 1/2 of clinical trials for cancer (121).
Intriguingly, silmitasertib potently inhibits both class I and II
DYRKs (122). The group did not report the IC50 for DYRK2;
however, DYRK3 IC50 was reported to be 18 nM (122).
Because the kinase domains of DYRK2 and DYRK3 are >90%
similar at the amino acid level, there is a good chance that
silmitasertib could indeed be a potent DYRK2 inhibitor as well.
Silmitasertib exhibits blood–brain barrier penetrance similar10 J. Biol. Chem. (2021) 296 100233to brain-penetrant DYR219 (118) and SM07883 (123) and
could therefore potentially pharmacologically target the
DYRKs in the brain.
A recently well-characterized DYRK2 inhibitor is the ac-
ridine analog, LDN192960 (26). Initially developed as a
Haspin inhibitor (124, 125), LDN192960 inhibited DYRK2
with 13 nM IC50 and exhibited antitumor activity in mouse
models of MM and TNBC (26). Interestingly, LDN192960
exhibited a ‘mixed’ mode of DYRK2 inhibition and cocrystal
structure of LDN192960 with DYRK2 revealed that two water
molecules mediated multiple hydrogen bonds between
LDN192960 and DYRK2 active pocket (26). Similar water
molecule–mediated interaction was also observed in the
cocrystal structure of DYRK1A with inhibitor DJM2005
wherein a water molecule facilitated hydrogen bonding to
further stabilize the inhibitor bound structure (2).
LDN192960 reduced tumor burden of syngrafted and
patient-derived xenografted mouse models of TNBC and
delayed bone degeneration of allografted MM mouse models
(26). In cells, LDN192960 exhibited potent cytotoxicity to-
ward cancer lines with minimal impact on noncancerous cells
(26). In fact, LDN192960 induced cytotoxicity to CD138+
primary myeloma cells of patients with significantly less
impact on matched peripheral mononuclear cells (26).
LDN192960 also exhibited additive effects in combination
with FDA-approved proteasome inhibitor carfilzomib in
inducing cytotoxicity in myeloma cells (26). LDN192960 was
bioavailable in vivo and a dose of 50 mg/Kg body weight was
sufficient to target neoplasia (26). Thus, LDN192960 inhibi-
ted DYRK2 in vivo and reduced 26S proteasome activity and
thereby targeted proteasome-dependent neoplastic diseases
such as TNBC and MM (25, 26).
Interestingly, curcumin inhibits DYRK2 with an IC50 of
5 nM and cocrystal structure revealed that curcumin binds to
the active site pocket of DYRK2 via hydrophobic interactions
(25). Curcumin is highly promiscuous, nonbioavailable, and
unstable in the serum-free solution and has been labeled as
both a pan-assay interference compound and an invalid
metabolic panacea (126). Curcumin aggregates at concentra-
tions greater than 15 μM, and most studies reporting
controversial biological targets for curcumin used high 20- to
100μM concentrations leading to possible false positives (126).
However, at lower 1- to 3μM concentrations, curcumin ablates
DYRK2-mediated 26S proteasome phosphorylation in cells,
reduces proteasome activity, and impairs cell proliferation in
TNBC and MM cell lines in vitro and in vivo (25). DYRK2 KO
cells exhibit no further off-target effects on proteasome activity
with curcumin (25). Although neither a viable drug scaffold
nor a highly potent kinase inhibitor, curcumin could serve as a
decent compound for DYRK2 inhibition when used with
proper controls.
In Table 2, we have listed those published inhibitors which
have been tested directly on DYRK2 activity in vivo or
in vitro along with a few interesting scaffolds identified in
medicinal chemistry publications (https://www.kinase-
screen.mrc.ac.uk/kinase-inhibitors) (127, 128). An impor-
tant observation is that not a single one of these DYRK2
Table 2
The published DYRK2 inhibitors currently available to the scientific community
Compound Structure %Inhibition/IC50 Other kinase targets References
1. Established potent and selective cell-permeable DYRK2 inhibitors
LDN192960 13 nM Haspin (10 nM); PIM3 (10 nM) PIM1/2;
DYRK1A (122 nM) DYRK1B;
DYRK3 (<3 nM)
(26, 124, 125)
GSK626616 <1 nM DYRK3 (0.7 nM); DYRK1A/B; CK (131)





EHT 5372 10.8 nM DYRK1A (0.22 nM)
DYRK1B (0.28 nM); CLK1 (22.8 nM)
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LY2835219 61 nM CDKs
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Table 2—Continued
Compound Structure %Inhibition/IC50 Other kinase targets References













Compound 6i 130 nM DYRK1A (210 nM) (142)
4. Other identified DYRK2 inhibitors
Curcumin 5 nM Highly nonspecific at >15-μM
concentrations
(25)
































The kinase in bold format indicates the original target reported for the compound. IC50 values are provided where available.
JBC REVIEW: DYRK2 in cancerinhibitors exhibit protumorigenic/pro–cell-proliferation
properties.
Conclusion and future perspectives
The controversial role of DYRK2 in cancer is evident
(Fig. 3). Recent review articles mentioned the conflicting
literature on DYRK2 (8, 28) and reported that mRNA
expression data show that DYRK2 levels are higher in invasive
breast carcinoma and lung adenocarcinoma than normal/
adjacent tissue control (8, 26). However, others maintain that
DYRK2 is a major tumor suppressor across all breast cancer
subtypes and that DYRK2 depletion promotes proliferation
(27). Indeed, being a CMGC kinase with a +1Pro active site,
there are expected redundancies between DYRK2, other
DYRKs, and possibly other CMGC kinases. A recent review12 J. Biol. Chem. (2021) 296 100233article provides a list of substrates exhibiting overlapping
DYRK kinases phosphorylating the same residues (8).
Furthermore, as a member of the EDVP complex, cancer-
specific mutations can alter DYRK2 substrate signature in
specific cancer cells, which could be either tumor suppressive
(3) or oncogenic (89). Although immunohistochemistry of
tumors in patients with glioma shows lower levels of DYRK2
correlates with poorer survival (65), a receptor tyrosine
kinase–transduced p53 null glioma mouse model exhibits
higher DYRK2 activity and potentially altered signaling with
diverse substrates (34). It is a definite possibility that we have
just seen the tip of the iceberg when it comes to deconvoluting
the redundancy and substrate overlap between the DYRKs and
other CMGC kinases. As already shown, meticulous inhibitor
screens and development of phospho-specific antibodies to
JBC REVIEW: DYRK2 in cancerthe substrates could pave the way to dissect specificities and
potential redundancies between the CMGC kinases (80).
With the establishment of genetic engineering CRISPR
KO/knock-in strategies and advanced quantitative phospho-
proteomics, we might be able to dig deeper into identifying
novel substrates and mechanisms in various cancer types. One
major way forward would be to generate a conditional KO
mouse model of DYRK2 in various cancer GEMM back-
grounds to study tumor development and thereby ascertain
the specific role of DYRK2 in each cancer subtype. A latest
study reports that mouse embryonic fibroblasts with DYRK2
deletion exhibits significant downregulation of major cell cycle
and proliferation drivers and markers such as Ki67, Aurora
kinase A, PLK1, Bub1, and Bub1b (19). Although not in a
cancer model, these observations are consistent with those
observed in TNBC tumors where depletion of DYRK2 leads to
reduced cell proliferation with greatly reduced Ki67 (10, 25,
26). However, DYRK2 could drive tumor-suppressor functions
pairing with substrates reported in Figure 3 and Table 1 or
other yet-undiscovered substrates in cancer type–specific
mechanisms (27). In future, the roles of DYRK2 in cancer
need to be approached in a more holistic way using multiple
controlled models in each study including but not limited to
genetic depletions and biochemical analyses, using specific
inhibitors, in vivo animal models, and in vitro cell-based assays.
Although overexpression of mRNA in cancers does indicate a
potential oncogenic role, correlating that to corresponding
increase of protein levels is important because mRNA and
protein level often do not correlate in tumor samples. Before
immunohistochemistry analysis on patient samples, proper
antibody optimization steps are necessary while data analyses
and sample size determinations need to be supported by
proper statistical principles. Furthermore, ectopic over-
expression of DYRK2 often results in false-positive substrate
phosphorylation/binding and such experiments should always
be accompanied with controls to ascertain the physiological/
bona fide roles of the kinase. Like its paralogue DYRK1A (111,
112) and many other kinases, DYRK2 may indeed play both
protumorigenic and antitumorigenic roles in different cancer
types and subtypes, which is often determined by spatiotem-
poral interactions between kinases and specific substrates.
Novel cancer therapeutic targets are a need of the hour, and
hence, controversies delaying the establishment of a potential
target or a tumor suppressor need to be objectively and quickly
addressed. Deconvolution of the enigmatic roles of DYRK2 in
various cancer types and subtypes should be prioritized among
those in the field making our tools and expertise available for
the greater scientific community in this endeavor.
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